Literature DB >> 17377401

Efficacy and tolerance of high-dose inhaled ipratropium bromide vs. terbutaline in intubated premature human neonates.

Michael Fayon1, Nawar Tayara, Christine Germain, Marie-Luce Choukroun, Eric Dumas De La Roque, Geneviève Chêne, Dominique Breilh, Roger Marthan, Jean-Louis Demarquez.   

Abstract

BACKGROUND: There is insufficient data to reliably assess the benefit of bronchodilators in ventilated premature neonates.
OBJECTIVES: To compare the efficacy/tolerance of inhaled ipratropium bromide (IB) vs. terbutaline (T) and to describe factors associated with their efficacy.
METHODS: A cross-over randomized controlled double-blind trial including intubated neonates with respiratory distress syndrome. Two puffs of IB or T were administered at 0, 20, 40 min. Passive respiratory system resistance (Rrs) and compliance (Crs) were measured at 0, 20, 40, 60 min. A positive response was defined as a >2 individual coefficients of variation decrease in Rrs or increase in Crs.
RESULTS: Twenty-one infants (gestational age (mean +/- SD): 27.3 +/- 1.6 weeks; birth weight: 947 +/- 250 g; postnatal age: 20 +/- 9 days) were included. At 60 min, no treatment effect for Rrs and Crs could be identified (cross-over analysis). Overall data (irrespective of order of administration) showed that after 6 puffs, the decrease in Rrs was greater in the IB vs. T group (-17.0 +/- 22.2% vs. -11.3 +/- 26.7%, respectively (NS)). Thirty-eight percent of infants responded to IB vs. 43% to T. However, in 19% of patients, decreased Crs was observed after 6 puffs of T. No marker of a positive or paradoxical response could be identified. Treatment was well-tolerated.
CONCLUSION: High doses of bronchodilators are required in ventilated neonates, but the positive response rate was <50%. Their long-term benefit remains to be proven. Copyright (c) 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17377401     DOI: 10.1159/000097448

Source DB:  PubMed          Journal:  Neonatology        ISSN: 1661-7800            Impact factor:   4.035


  6 in total

Review 1.  Optimizing respiratory management in preterm infants: a review of adjuvant pharmacotherapies.

Authors:  Jenny K Koo; Robin Steinhorn; Anup C Katheria
Journal:  J Perinatol       Date:  2021-07-09       Impact factor: 2.521

2.  Airway Hyperreactivity Is Delayed after Mild Neonatal Hyperoxic Exposure.

Authors:  Harris Onugha; Peter M MacFarlane; Catherine A Mayer; Akua Abrah; Anjum Jafri; Richard J Martin
Journal:  Neonatology       Date:  2015-05-22       Impact factor: 4.035

Review 3.  Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants.

Authors:  Geraldine Ng; Orlando da Silva; Arne Ohlsson
Journal:  Cochrane Database Syst Rev       Date:  2016-12-14

4.  Aerosol therapy in relation to retinopathy of prematurity in mechanically ventilated preterm infants.

Authors:  Mei-Chin Yang; Hsiu-Feng Hsiao; Hsiu-Li Tseng; Ya-Wen Chiu; Yi-Hao Weng
Journal:  BMC Pulm Med       Date:  2019-08-13       Impact factor: 3.317

5.  Response to first dose of inhaled albuterol in mechanically ventilated preterm infants.

Authors:  Thomas M Raffay; Mandy Brasher; Brooke C Place; Abhijit Patwardhan; Peter J Giannone; Henrietta Bada; Philip M Westgate; Elie G Abu Jawdeh
Journal:  J Perinatol       Date:  2021-05-25       Impact factor: 2.521

6.  Inhaled bronchodilator use for infants with bronchopulmonary dysplasia.

Authors:  J L Slaughter; M R Stenger; P B Reagan; S R Jadcherla
Journal:  J Perinatol       Date:  2014-08-07       Impact factor: 2.521

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.